Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 23708665)

1.

Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.

Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H.

Oncogene. 2014 Apr 24;33(17):2215-24. doi: 10.1038/onc.2013.172. Epub 2013 May 27.

2.

Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.

Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK, Rui H.

Cancer Res. 2010 Feb 15;70(4):1711-21. doi: 10.1158/0008-5472.CAN-09-2314. Epub 2010 Feb 2.

3.

Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.

Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA.

Horm Cancer. 2013 Feb;4(1):36-49. doi: 10.1007/s12672-012-0127-5. Epub 2012 Nov 27.

4.

The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.

Liu R, Zhou Z, Zhao D, Chen C.

Mol Endocrinol. 2011 Jul;25(7):1137-44. doi: 10.1210/me.2010-0497. Epub 2011 May 12.

PMID:
21566082
5.

Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.

Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H.

Oncogene. 2015 Jun 22. doi: 10.1038/onc.2015.193. [Epub ahead of print]

PMID:
26096934
6.

Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.

Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA.

Breast Cancer Res Treat. 2011 Jul;128(1):45-55. doi: 10.1007/s10549-010-1078-6. Epub 2010 Jul 28.

7.

Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment.

Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H.

Breast Cancer Res. 2013;15(5):R73.

8.

p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.

Liang Y, Wu J, Stancel GM, Hyder SM.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):173-82. Epub 2005 Jan 28.

PMID:
15860260
9.

Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.

Knox AJ, Scaling AL, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA, Horwitz KB.

Breast Cancer Res. 2014 Aug 13;16(4):418. doi: 10.1186/s13058-014-0418-6.

10.

Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA.

Breast Cancer Res. 2011 Jan 28;13(1):R11. doi: 10.1186/bcr2819.

11.

A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.

Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV.

J Biomol Screen. 2012 Oct;17(9):1211-20. Epub 2012 Jun 29.

12.

Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.

Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA.

Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5774-9. doi: 10.1073/pnas.0706216105. Epub 2008 Apr 7.

13.

STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.

Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD.

Breast Cancer Res. 2012 Jan 20;14(1):R16.

15.

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.

Bhargava R, Beriwal S, Striebel JM, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):113-8. doi: 10.1097/PAI.0b013e3181b94ff1.

PMID:
19801938
16.

Global profiling of prolactin-modulated transcripts in breast cancer in vivo.

Sato T, Tran TH, Peck AR, Liu C, Ertel A, Lin J, Neilson LM, Rui H.

Mol Cancer. 2013 Jun 12;12:59. doi: 10.1186/1476-4598-12-59.

17.

PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.

Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H.

Am J Pathol. 2010 Dec;177(6):2971-83. doi: 10.2353/ajpath.2010.090399. Epub 2010 Oct 15.

18.

Epidermal growth factor suppresses induction by progestin of the adhesion protein desmoplakin in T47D breast cancer cells.

Pang H, Rowan BG, Al-Dhaheri M, Faber LE.

Breast Cancer Res. 2004;6(3):R239-45. Epub 2004 Mar 18.

19.

Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors.

Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM.

Horm Cancer. 2012 Aug;3(4):160-71. doi: 10.1007/s12672-012-0114-x. Epub 2012 May 9.

PMID:
22569706
20.

STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.

Walker SR, Nelson EA, Yeh JE, Pinello L, Yuan GC, Frank DA.

Mol Cell Biol. 2013 Aug;33(15):2879-90. doi: 10.1128/MCB.01620-12. Epub 2013 May 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk